Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT01246076
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Mayo Clinic Scottsdale AZ, Scottsdale, Arizona, United States
Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment
- Conditions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2014-04-04
- Target Recruit Count
- 20
- Registration Number
- NCT01246557
- Locations
- 🇪🇸
Centro Médico Teknon, Barcelona, Spain
🇪🇸Hospital Universitari Valle Hebron, Barcelona, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Interventions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT01246622
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Fundación General de la Universidad de Salamanca
- Target Recruit Count
- 61
- Registration Number
- NCT01243476
- Locations
- 🇪🇸
Hospital Clínic i Provincial, Barcelona, Spain
🇩🇪Universitaetsklinikum Carl Gustav Carus der Technischen Universitaet Dresden, Dresden, Germany
🇪🇸Instituto Catalán de Oncología de Gerona, Gerona, Spain
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 646
- Registration Number
- NCT01239797
- Locations
- 🇺🇸
Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Ut Southwestern Medical Center, Dallas, Texas, United States
Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01222195
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT01222754
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study of Everolimus (RAD001) in Combination With Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 44
- Registration Number
- NCT01218555
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01217957
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Mt Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 289
- Registration Number
- NCT01216683
- Locations
- 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸Graham Hospital Association, Canton, Illinois, United States
🇺🇸Mcdonough District Hospital, Macomb, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.